cases (1.9%) with reservoir-related mechanical failure or complication requiring revision surgeries. Of those four, two cases (0.95%) were mechanical failures resulting from the reservoir leaking. In both cases, the cause of leak was identified as an intrinsic point of weakness at the apex of the reservoir caused by inward folding of an unfilled segment. The inward folding of the reservoir was observed at volumes of 60 to 80 mL. In the remaining two cases (0.95%), the reservoir complication observed was refractory abdominal muscle pain related to ectopic location and intra-fascial placement. In both cases, revision surgery with reservoir repositioning resolved the pain.
INTRODUCTION AND OBJECTIVES:
Ischemic priapism unresolved by medical therapy typically progresses to surgical management with a distal or proximal penile shunt. Due to the infrequent nature of these cases, little has been reported regarding complications. As other treatment options arise, such as immediate penile prosthesis placement for long standing ischemic priapism, it is important to consider the hospital stay and complication rates of the current standard of care.
METHODS: A retrospective cross sectional analysis was performed using the National Surgical Quality Improvement Project (NSQIP) database. Cases of penile shunts were identified from 2006-2014 using the ICD-9 procedure codes 54435 for distal corporoglanular shunt, 54430 for corporospongiosal shunt, and 54420 for corporosaphenous shunt. Univariate analysis was performed to compare 30-day complication rates for the different types of shunts.
RESULTS: A total of 104 patients underwent operative management for ischemic priapism, 58.7% of which were listed as emergent cases. Mean age was 44.6 AE 13 years. Of the entire sample, 31.7% underwent a corporoglanular shunt, 54.8% underwent a corporospongiosal shunt, and 13.4% underwent a corporosaphenous shunt. Length of stay was longer for corporospongiosal shunts (2.19AE1.98) than corporoglanular (1.88AE2) or corporosaphenous shunts (1.5AE1.23). Post-operative complications occurred in 4.81% of the sample. The more common complications were urinary tract infection (1.9%) and blood transfusion (1.9%). Corporospongiosal shunts exhibited higher overall complications (7.02%), followed by corporoglanular (3.03%) and corporosaphenous shunts (0%). Reoperation occurred in 8.45% of proximal shunts, versus 3.03% of corporoglanular shunts. Reoperation was more common if the case was listed as emergent (9.84%).
CONCLUSIONS: Ischemic priapism unresponsive to medical therapy continues to be a challenging problem. It appears that though complication rates overall are low for both proximal and distal penile shunts, the reoperation rate is substantial for proximal penile shunts. This should be considered when determining whether to perform a proximal shunt versus placement of an immediate penile prosthesis. The development of the inflatable penile prosthesis (IPP) ushered in a new era in the management of erectile dysfunction. Despite multiple innovations to improve the function and reliability, there is no current data comparing the biomechanical properties of these devices. We aim to compare the resistance of the Coloplast Titan to the AMS LGX penile prosthesis cylinders to longitudinal (penetration) and horizontal (gravity) forces.
METHODS: We compared two cylinder sizes from each company: Coloplast Titan (18cm and 20cm) and the AMS LGX (18cm and 21cm). To evaluate axial rigidity, which simulates forces during penetration, we performed a longitudinal load compression test to determine the load required to cause the cylinder to kink. To test horizontal rigidity, which stimulates the horizontal forces exerted by gravity, we performed a modified cantilever test and measured the degrees of bend for each device. All devices were tested at 10, 15, and 20 PSI to simulate in-vivo pressures.
RESULTS: The main outcome measurement for the longitudinal load test (penetration) was the force required for the inflated cylinder to bend, thereby impacting its rigidity. The main outcome for the horizontal rigidity test (gravity) was the angle of displacement, in which a lower angle represents a more horizontally rigid device. Longitudinal column testing (penetration) demonstrated that less force was required for the AMS device to kink compared to the Coloplast implant across all three-fill pressures tested. The Coloplast Titan also had a lower angle of displacement on the modified cantilever test (gravity) when compared to the AMS implant across all fill pressures.
CONCLUSIONS: The Coloplast Titan demonstrated greater resistance to both longitudinal (penetration) and horizontal (gravity) forces in this study. The AMS device was more sensitive to fill pressures. In contrast, the Coloplast Titan 0 s ability to resist both types of forces was less dependent on the device fill pressure.
Source of Funding: None

PD25-12 EVALUATION OF INFLATABLE PENILE PROSTHESES: HOW THEY PERFORM IN THE LAB?
Paholo Barboglio Romo*, Harshitha P. Chikkatur, Sahana Beldona, Yooni Yi, Tim M. Bruns, Bahaa S. Malaeb, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: We sought out to describe and evaluate the existing inflatable penile prostheses (IPP) in an independent lab setting.
METHODS: New IPPs were obtained from the two manufacturers: American Medical Systems (Minnetonka, MN) and Coloplast (Minneapolis, MN). The AMS700 LGX (18 cm), CX (18 cm), CXR (15 cm), Coloplast Titan-Touch (18 cm) and Titan-Narrow (14 cm) were interrogated. We measured internal pressure, length and girth of the cylinders at 2ml increments. A urodynamic individual transducer connected to an analog amplifier and recording system was utilized to measure pressure. Rigidity and axial loading of the different IPPs were evaluated with a compression system. RESULTS: Regular-sized prostheses were inflated to 22 ml and narrow prostheses to 16 ml. Coloplast Titan Touch showed a girth of 17.8 mm at 22 ml compared to 15.6 mm for AMS700 LGX, and 16.5 mm for CX. AMS700 LGX increased a length of 13 mm from baseline, a feature that was unique to that prosthesis among all those tested (Figure 1) . Rigidity curves as assessed by compression showed significant variability with both Titan prostheses and AMS CX-R exhibiting similar curve pattern and requiring a higher load to reach 50% Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e505 compression. The buckling experiment showed different patterns of deformity (Figure 2) . CONCLUSIONS: Data suggests that these prostheses exhibit significant physical differences. The clinical impact of these differences is poorly elucidated. These variations in the prostheses behaviors could be considered by the physician and the patient while objectively assessing the choice of the prosthesis. These findings could aid in objective patient counseling. Men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) are two times more likely to report mental health diagnoses such as anxiety and depression. Additionally, men reporting a history of sexual abuse are at increased risk for symptoms of CP/CPPS. Male veterans with mental health diagnoses are also at increased risk of lower urinary tract symptoms. We hypothesize that an association exists between CP/ CPPS and post-traumatic stress disorder (PTSD) in young male veterans, and that these veterans may be more likely to report a history of sexual trauma or be subject to invasive urologic procedures.
Source of Funding
METHODS: We reviewed VA administrative data from October 1, 2010 to September 30, 2015 for male veterans, ages 18-45 diagnosed with PTSD (ICD-9 code 309.81). Medical records were then examined for pelvic pain diagnoses including chronic pelvic pain (789.09; 338.29, 608.9, 625.5, 788.99, 788.99, 596.9, 599/599.8, 625 .5), chronic prostatitis (601.0, 601.1, 601.9, 600.90-1, 600.0-1; 601.8, 602.8) and pain associated with voiding (788.1, 788.6). Veterans with diagnoses of spinal cord injury and neurogenic bladder were excluded. Records were examined for ICD-9 diagnoses of history of sexual trauma (general, military or any) and CPT codes for cystoscopic, urodynamic, bladder outlet and prostatic ultrasound procedures. Data were obtained for a preparatory-to-research pull.
RESULTS: Our initial database query yielded approximately 392,000 veterans with a diagnosis of PTSD and 1.3 million veterans without documented PTSD. Veterans with PTSD were more likely to have a diagnosis of CP/CPPS than their non-PTSD counterparts (18.5% vs. 8.7%, p<0.001). Veterans with PTSD were more likely to have a history of military sexual trauma (2.8% vs. 0.5%, p<0.001) or non-military sexual trauma (0.4% vs. <0.1%, p<0.001) compared to veterans without PTSD. Young veterans with PTSD were also more likely to have a cystoscopy (0.8% vs. 0.5%, p<0.001) and/or undergo urodynamics (1.0% vs. 0.5%, p<0.001) versus those without PTSD. Rates of transrectal ultrasound-guided prostate procedures and bladder outlet procedure were not significantly different between the two groups.
CONCLUSIONS: Young male veterans with PTSD are twice as likely to carry a diagnosis of CP/CPPS. Those with PTSD and CP/ CPPS are six times more likely to report a history of sexual trauma and are twice as likely to undergo a certain urologic procedures. We recommend improved assessment for sexual trauma and consideration of referral to mental health providers by uroIogists treating young male veterans with CP/CPPS. This abstract describes the rate of complete urinary continence at 5 years in this prospective, multicenter post-approval study of sacral neuromodulation (SNM) with the InterStimâ System. Subjects with bothersome symptoms of overactive bladder (OAB) including urinary urge incontinence (UI) and/or urgency-frequency (UF), who had not exhausted all medication options (failed at least 1 anticholinergic medication and had at least 1 medication not tried) were included in the InSite study.
METHODS: Subjects with successful test stimulation received an InterStim implant. Implanted subjects were followed at 3 months, 6 months, and annually to 5 years post-implant. Therapeutic success for UI subjects was defined as a !50% improvement in average leaks/day from baseline. Complete continence was defined as 100% improvement in leaks/day compared to the baseline. Therapeutic success and complete urinary continence through 5 years were evaluated for all implanted UI subjects with diary data at baseline and follow-up visits (completers analysis).
RESULTS: Of 272 OAB subjects that were implanted, 91% were female and the mean age was 57 years. Of these, 202 subjects qualified as having UI based on the baseline voiding diary and they had an average of 3.1AE2.7 leaks/day. As shown in the figure, over time the UI therapeutic responder rate was consistently high, ranging from 76% through 83% through different follow-up visits. The UI therapeutic responder rate at 5 years was 76% (95% CI: 69-84%). From 3 months
